VXRT Vaxart, Inc.
USHealthcareAs of 2026-07-08 16:00
Why VXRT matters now
Vaxart, Inc. (VXRT) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.55 with +0.00% on the session and $133.1M in market capitalization; recent performance reads 1-month -9.84% and YTD +57.14%.
The latest financial table shown here is Q1 2026, with revenue of $39.2M, net income of $5.2M, and EPS of $0.02. Investors can compare that operating picture with valuation signals such as P/E 9.17 and FCF yield 11.1%.
The latest indexable market news headline is "Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.00; recent insider activity includes Watson W. Mark filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
9.17
PEG
0.07
P/B
1.41
P/S
0.52
EV/EBITDA
1.91
DCF Value
$-35.22
FCF Yield
11.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
14.9%
Net Margin
14.5%
ROE
61.4%
ROA
20.6%
ROIC
35.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $39.2M | $5.2M | $0.02 |
| Q4 2025 | $104.2M | $55.0M | $0.23 |
| FY 2025 | $237.3M | $16.3M | $0.07 |
| Q3 2025 | $72.4M | $-8.1M | $-0.04 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.00
Target (Median)
$2.00
Target Range
$2.00 - $2.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.09
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.